Last reviewed · How we verify
NCT07444931: SCAR
Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD
trial in Coronary Arterial Disease (CAD) in 1,500 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Tampere Heart Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 5 January 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 3 locations across Romania, Israel, Moldova |
Conditions studied
- Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →
- Sudden Cardiac Arrest — all drugs for Sudden Cardiac Arrest →
- Sudden Cardiac Death — all drugs for Sudden Cardiac Death →
Sponsor
Tampere Heart Hospital
Who can join
Adults 18 to 75, any sex, with Coronary Arterial Disease (CAD) or Sudden Cardiac Arrest. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long-term sudden cardiac death (abbreviation: SCAR) focuses on improving the predictability of sudden cardiac death (SCD) in patients diagnosed with coronary artery disease. The aim of the study is to determine the predictive value of measurable biological variables (including genetic factors, cardiac electrical activity, biological markers measured from circulation, and coronary artery anatomy) as well as the patients' psychosocial factors in predicting SCDs. The purpose of this study is the identification of a subgroup of coronary artery disease patients at sufficiently high risk in whom it may be possible to prevent sudden cardiac arrests and subsequent deaths using implantable cardioverter-defibrillators. The study is intended to establish a clear foundation for future interventional studies targeting high-risk coronary artery disease patients. The primary endpoint of the study is SCD/sudden cardiac arrest (SCA) or a comparable malignant arrhythmic event (i.e., resuscitation). Secondary endpoints include other major cardiovascular events occurring during the follow-up period (such as cerebrovascular events, myocardial infarctions, revascularizations, and new arrhythmias like atrial fibrillation following procedures or after the patient has been discharged following recruitment) or the occurrence and mortality of other significant life-threatening diseases (such as cancer). Secondary endpoints also include poor success in secondary prevention, which can be assessed through completed medication purchases and the achievement of secondary prevention goals. This observational, prospective study includes collecting multimodal data from hospitals in Finland (TAUH), Israel (HYMC), Moldova (IMSP) and Romania (UMFCD). Each participating institution has followed a process structured by Tampere Heart Hospital (TAUH) for securing permissions in line with EU and national regulations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07444931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Arterial Disease (CAD)
Currently open trials in the same condition.
- NCT07444957 — Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease · recruiting
- NCT06855537 — Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques · Phase 4 · recruiting
- NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
- NCT07093788 — Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions · NA · recruiting
- NCT07041359 — Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease W · Phase 4 · recruiting
Other Tampere Heart Hospital trials
Trials by the same sponsor.
- NCT06804122 — Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension · NA · recruiting
- NCT06804499 — Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07444931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere Heart Hospital
- Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07444931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing